Amsterdam Molecular Therapeutics Ends Glybera Development, Halves Workforce
This article was originally published in The Pink Sheet Daily
AMT halves head count and restructures following second rejection by European regulators of its potential gene therapy, Glybera.
You may also be interested in...
After three previous negative votes, the Netherlands biotech uniQure gains the first positive opinion from the Committee for Medicinal Products for Human Use for a gene therapy in Europe. Glybera is used to treat the ultra-rare condition lipoprotein lipase deficiency.
Amsterdam Molecular Therapeutics plans to be acquired by a newly formed private company, uniQure, and to delist from Euronext.
Oxford BioMedica and U.S. researchers at the Mayo Clinic are to use the company's lentivirus vector to deliver two prostaglandin-related genes into the front of the eye to alleviate glaucoma.